Floxuridine (FUDR)
Sponsors
Memorial Sloan Kettering Cancer Center, Corewell Health West, Benaroya Research Institute
Conditions
CholangiocarcinomaCholangiocellular CarcinomaCholangiolar CarcinomaColorectal Adenocarcinoma Metastatic to the LiverColorectal CancerIntrahepatic CholangiocarcinomaLiver MetastasesPancreatic Adenocarcinoma
Phase 2
Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
CompletedNCT01862315
Start: 2013-05-31End: 2025-03-18Updated: 2025-03-19
Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver
WithdrawnNCT03069950
Start: 2017-02-28End: 2019-05-16Updated: 2019-05-21
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
CompletedNCT03693807
Start: 2018-10-18End: 2024-06-27Updated: 2026-02-06
Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
Active, not recruitingNCT03856658
Start: 2019-02-05End: 2025-12-31Updated: 2025-06-17
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
NCT04668976
Start: 2020-11-25End: 2024-12-31Target: 100Updated: 2020-12-21
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
RecruitingNCT04891289
Start: 2021-05-07End: 2027-05-01Target: 164Updated: 2026-04-01